Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Feb 15, 2021 9:32pm

408 Views

Post# 32570457

Wake -UP!!, time for some excitment

After a long period of next to nothing happening, ONC is long over due for some news, stock movement ...anything.
The list of "catalysts" & "milestones" is huge.
Analysts have a consensus rating of $7.33 USD or $9.45 CDN
Those BTW in of them selves are extreamly low, compared to opportunies.
Ithas been discussed & ratiolized that if Pelareorp egets to market as an imune system primer, the price would be well above $25 ps.
So, with only 2 weeks before Q4 results, perhaps we will have some news ahead of that?

Worst case we wait until Q4 update. Typically early March

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand